2020 Targeted Therapies of Lung Cancer (TTLC) Meeting
Conference | English
Image For Activity Cover
Availability
On-Demand
21 Courses
Cost
$0.00
Credit Offered
No Credit Offered
Given the rapid pace of change in the lung cancer field, investigators and clinicians face continual pressure to remain abreast of the latest advances in treatment and therapy. The IASLC Targeted Therapies of Lung Cancer Meeting (TTLC) has long sought to assist with that ongoing challenge, providing a forum for the lung cancer community to learn about the newest treatments and how they can be most effectively incorporated into clinical practice.

This year, TTLC is proud to celebrate its 20th anniversary, and on behalf of the IASLC leadership, Board of Directors and conference organizers, we want to thank you for joining us in Santa Monica for this unique event. Over the next three days, you will get an exclusive look at relevant targets for new therapies; data on pre-clinical and early clinical statistics for each of the drugs directed against these targets; presentations on early predictive biomarkers; debates on controversial topics and much more.
The IASLC 2024 Targeted Therapies of Lung Cancer meeting is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses.
Upon completion of this activity, the participants should be able to: 
  • Understand data on relevant targets for new therapies. 
  • Understand data on preclinical and early clinical trials for each of the drugs directed against relevant targets.
Program Co-Chairs: 
  • Paul A. Bunn, Jr., MD
  • Roy S. Herbst, MD, PhD
  • Leora Horn, MD
  • Suresh S. Ramalingam, MD
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
If you need assistance with this activity, please email: education@iaslc.org.
Powered By